Navigation Links
Seattle Reproductive Medicine Study Investigates Newly Formulated Medications for Luteal Support in IVF
Date:1/14/2009

SEATTLE, Jan. 14 /PRNewswire/ -- Patients undergoing in vitro fertilization self-administer daily injections of progesterone from two to eight weeks after the egg retrieval procedure. The outcome of a new study of an investigational formulation of progesterone could replace these painful intramuscular injections of progesterone in oil with less painful subcutaneous injections.

Seattle Reproductive Medicine (SRM), along with eight other large fertility centers across the country, has been selected to participate in a study designed to compare the safety and effectiveness of an investigational aqueous formulation of progesterone that will be compared to a form of progesterone administered intra-vaginally.

"For years patients have complained about these injections. One shot may be tolerable, but many weeks of daily injections is a long time for this degree of discomfort," says Dr. Michael Soules, MD, SRM's managing partner. Dr. Soules is the principle investigator for the U.S. arm of this study. He adds, "Being a large practice affords us the opportunity to make these types of studies available to our patients. These studies help patients offset the cost of their treatment."

Progesterone supplementation is routinely given after egg recovery for two weeks or longer to assist embryo implantation and support of the uterine lining. Progesterone in oil injected intramuscularly is the usual means of administration. These self-administered injections can be quite painful. The drug being tested is a new formulation of an existing approved medication. If outcome, tolerability and safety are the same or better with the investigational formulation of progesterone then patients would no longer be subjected to these drugs.

Study participants must be in an IVF cycle and will receive study related medications valued near $300 at no cost and a $1500 payment for participation. Enrollment in the study is now open and patients interested in participating should contact Seattle Reproductive Medicine for more information.

About Seattle Reproductive Medicine

Seattle Reproductive Medicine is led by a nationally recognized team of seven physicians who offer comprehensive, state-of-the-art assistance for couples with infertility and women with reproductive endocrine problems. Drs. Soules and Klein have received several National Institutes of Health (NIH) research grants over the years and the Clinic's work in reproductive aging has received prominent media coverage in Seattle. Seattle Reproductive Medicine is a member of IntegraMed, an exclusive network of 140 physicians and scientists limited to the highest performing infertility practices. One of every five procedures in the United States is performed in an IntegraMed practice. For more information, visit http://www.SeattleFertility.com.


'/>"/>
SOURCE Seattle Reproductive Medicine
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. A Place for Mom COO Makes Seattles 40 Under 40 List
2. Seattle Surgeon Named 2007 Veterinarian of the Year
3. Math battling cancer, deciding lifes challenges lead list as INFORMS meet in Seattle
4. WELLESSE ALL DAY ENERGY(TM) - Sponsors of the UW Medical Center 2007 Seattle Marathon
5. MultiCare Joins Seattle Cancer Care Alliance Network
6. Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment
7. Upscale Seattle-Based Skincare Clinic Expands Into California With Unique Custom Tailored Skincare Approach
8. Seattle-Based Law Firm Williams Kastner Receives Significant Defense Verdict in Trade Secret Business Litigation Case
9. Seattle-Based Marsha Rivkin Center for Ovarian Cancer Research Appoints Nancy Sclater, Executive Director
10. Compressus Announces Seattle Radiologists Interoperability Implementation
11. Seattle Laces Up To Beat the Bridge and Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology: